News

MedPage Today on MSN1d
Wegovy Pill Under Review; FDA Lifts Obesity Trial Clinical Hold; SGLT2s and Surgery
The FDA will decide whether to approve a once-daily, 25 mg oral formulation of semaglutide (Wegovy) by the end of 2025. If ...
Why Novo missed its sales estimates on weight-loss drug Wegovy: CEO
Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...
US judge sides with FDA's removal of Lilly's weight loss drug from shortage list
A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight loss and ...
How copycats of Wegovy, Zepbound created a billion-dollar market
Novo Nordisk cut 2025 sales forecast citing competition from compounded versions of its Wegovy weight-loss drug. Invezz takes ...
BioSpace4h
Novo Vows Smoother Market Waters for Wegovy—But Analysts Are Skeptical
The FDA in February formally declared the end of the semaglutide shortage, which Novo Nordisk expects will help improve the ...
FDA stops sale of generic versions of Ozempic and Wegovy: What it means for patients
Receiving a generic version of Ozempic or Wegovy from a compounding pharmacy is normally both easier to access and cheaper.
Healthline2d
Wegovy Reduced Inflammation, Scarring in People with Serious Liver Disease
Wegovy (semaglutide) could offer a new option to treat severe liver disease based on new clinical trial evidence. The GLP-1 ...
BioSpace2d
Novo’s Wegovy Inches Closer to Becoming First FDA-Approved GLP-1 Weight-Loss Pill
The FDA accepted Novo Nordisk's NDA for an oral formulation of Wegovy. The agency is expected to release its verdict on the ...
The Pharma Letter1d
FDA accepts filing application for oral Wegovy 25mg
The US Food and Drug Administration (FDA) accepted Novo Nordisk’s New Drug Application (NDA) submission for an ...